Eisai to file first in-house anticancer in major markets for breast cancer
This article was originally published in Scrip
Executive Summary
Eisai plans to file its new chemotherapy drug eribulin (E7389) – its first oncology drug developed in-house – for pre-treated locally advanced or metastatic breast cancer in Japan, the US and the EU by the end of its fiscal year ending March 2010 after it improved overall survival in patients who had received at least two prior treatments in a pivotal Phase III trial.